Compare Cytokinetics Inc (CYTK) vs Ralph Lauren Corp (RL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Ralph Lauren Corp — how do they compare? Cytokinetics Inc trades at $62.02 (market cap $8.50B), while Ralph Lauren Corp trades at $367.77 (market cap $21.52B). The key difference: Ralph Lauren Corp is far larger — about 2.5× Cytokinetics Inc's market cap, and Ralph Lauren Corp pays a 1.11% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Ralph Lauren Corp for 84 Days on average.
| CYTK | RL | |
|---|---|---|
Market Cap | $8.50B | $21.52B |
Volume | 2,395,556 | 454,217 |
Sector | Health | Consumer Cyclical |
52-Week High | $87.26 | $414.25 |
52-Week Low | $54.76 | $309.29 |
Typical Hold Time | 19 Days | 84 Days |
Enterprise Value | $8.60B | $22.58B |
Dividend Yield | — | 1.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
Ralph Lauren (RL) trades at $367.39, down 0.35% with a bearish technical signal despite strong fundamentals. The company demonstrates robust profitability with 70.27% gross margins and 37.54% ROE, while consistently beating earnings estimates. Recent news highlights global expansion through new store openings and AI-driven customer experience enhancements. Cash flow remains positive at $258.80M for 2025, supporting the $1.00 dividend declared for October 2026 payment.
The stock presents a compelling value opportunity with analyst consensus target of $456.67 representing 24% upside. Strong brand positioning and operational efficiency drive growth, though competitive pressures and market volatility pose risks. Institutional sentiment remains bullish with 67% buy ratings, suggesting confidence in the company's luxury market strategy and financial performance trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Ralph Lauren Corp
Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →
